Atazanavir – Essential Info for HIV Treatment

When working with Atazanavir, a protease inhibitor used to manage HIV infection. Also known as Reyataz, it blocks the HIV protease enzyme and lowers viral load. This drug is a core part of modern antiretroviral therapy, combination treatment for HIV and is often paired with other drug classes to prevent resistance. Patients living with HIV, human immunodeficiency virus rely on Atazanavir to keep the virus suppressed while maintaining a manageable side‑effect profile.

Why Atazanavir Matters in Modern HIV Care

Atazanavir’s main attribute is its ability to inhibit the HIV protease enzyme, which is essential for viral particle maturation. Atazanavir is typically dosed at 300 mg once daily with a boosting agent like ritonavir, although a low‑dose regimen (200 mg) exists for patients with mild liver issues. Its metabolism hinges on the CYP3A4 pathway, so clinicians watch for interactions with common meds such as calcium channel blockers or certain antifungals. One key side effect is hyperbilirubinemia – patients may notice a yellow tinge to their skin, but this rarely signals liver damage and often resolves on its own. Another attribute is a relatively low impact on lipid levels compared with some other protease inhibitors, making it a preferred option for patients with cardiovascular risk factors. Drug resistance is another critical factor. When HIV develops mutations in the protease gene, Atazanavir’s efficacy can wane, which is why it’s usually prescribed as part of a triple‑drug regimen that includes two nucleoside reverse transcription inhibitors (NRTIs). Monitoring viral load every 3–4 months helps catch resistance early, allowing a switch to a newer agent before treatment failure occurs. The drug’s safety profile also makes it suitable for pregnant women in the second and third trimesters, though clinicians still assess risk‑benefit on a case‑by‑case basis. Beyond the clinical science, practical considerations shape its use. Generic versions of Atazanavir have entered the market, offering cost savings without sacrificing quality. Patients are advised to store the tablets at room temperature, keep the bottle tightly closed, and avoid crushing the pills because the coating is designed for slow release. Regular liver function tests and bilirubin checks are part of routine follow‑up, especially during the first few weeks of therapy. Our collection below pulls together in‑depth articles on related topics – from comparing Atazanavir with other protease inhibitors to navigating drug‑interaction pitfalls, from managing side effects like jaundice to understanding the latest resistance data. Whether you’re a patient looking for clear guidance or a practitioner scouting quick reference points, the posts that follow cover the full spectrum of Atazanavir‑related knowledge.